Pulmonary Function after Proton Therapy for Hodgkin Lymphoma.

Area of Science:

• Oncology
• Radiation Oncology
• Pulmonary Medicine

Background:

• Hodgkin lymphoma (HL) survivors face risks of pulmonary dysfunction from cancer treatments.
• Pulmonary function tests (PFTs) are crucial for assessing treatment-related lung toxicity.
• Proton therapy offers improved dosimetry, potentially reducing side effects.

Purpose of the Study:

• To investigate the impact of proton therapy on pulmonary function tests (PFTs) in Hodgkin lymphoma survivors.
• To evaluate the safety and efficacy of proton therapy regarding pulmonary toxicity.

Main Methods:

• A cohort of 15 patients with mediastinal HL was monitored.
• Patients received combination chemotherapy and involved-node proton therapy.
• Pulmonary function tests (PFTs) were conducted pre-treatment and at 6 and 12 months post-therapy.

Main Results:

• Analysis included 12 patients; 3 were excluded.
• Mean forced vital capacity (FVC) and FEV1 remained stable from baseline to 12 months.
• Mean diffusing capacity for carbon monoxide (DLCO) showed improvement at 12 months post-therapy.

Conclusions:

• Proton therapy did not result in unexpected pulmonary changes in HL survivors within 12 months.
• Long-term follow-up and larger cohort studies are recommended for validation.